

IN VITRO RESPONSE TO CHEMOTHERAPY IN ACUTE LEUKEMIA

Thesis

**Submitted in Partial Fulfillment of
M.D. Degree in Clinical Pathology**

By

Hanaa Mohamed El-Sayed Afifi
(M.B., B. Ch. & M.Sc. "Clinical Pathology" , Ain Shams)

Supervisors

Prof. Dr. Tarif Hamza Salam
Prof. of Clinical Pathology
Faculty of Medicine, Ain Shams University

Prof. Ahmed Samy Khalifa
Prof. of Pediatric Medicine
Faculty of Medicine, Ain Shams University

Dr. Aisha Ali Osman Fakeir
Assistant Professor of Clinical Pathology
Faculty of Medicine, Ain Shams University

**FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY
1993**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ

خَلَقَ الْإِنْسَانَ مِنْ عَلَقٍ

اقْرَأْ وَرَبُّكَ الْأَكْبَرُ الَّذِي عَلَّمَ بِالْقَلَمِ

عَلَّمَ الْإِنْسَانَ مَا لَمْ يَعْلَمْ

المطلع، ١٠-٩



ACKNOWLEDGEMENT

I wish to express my deep appreciation and gratitude to Professor Dr. Tarif Hamza Salam, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under his supervision and helpful guidance. His advices were always stimulating and especially essential to complete this work.

I wish to express my sincere thanks and gratitude to Dr. Ahmed Samy Khalifa, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his great help and continuous encouragement.

I also express my deep thanks and gratitude to Dr. Aisha Ali Osman Fakeir, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great support, encouragement, patience, enthusiasm, criticism, fruitful comments and help without which this work would have never come to light.

I am also grateful to Dr. Ahmed Abd El-Salam El-Meligy, Professor of Pharmacology, Faculty of Medicine, Ain Shams University for his great cooperation and generous help.

To my family, to my patients and to every one who participated in some way or the other, to let this work come to such a final picture, I owe my thanks and gratitude.

LIST OF TABLES

Table 1: Drugs used in the treatment of acute lymphoblastic leukemia	(6)
Table 2: Clinical findings at presentation of the examined group of patients (pediatric age group) ...	(97)
Table 3: Laboratory findings in the pediatric age group of patients	(98)
Table 4: Clinical characteristics of patients and optical density of control cultures of the pediatric age group of patients	(99)
Table 5: In vitro chemosensitivity results expressed in the form of INT reduction inhibition % of control ..	(100)
Table 6: Clinical findings at presentation of the examined group of patients (adult age group)	(104)
Table 7: Laboratory findings in adult age group of patients	(105)
Table 8: Clinical characteristics of patients and optical densities of control cultures of the adult age group of patients	(106)

Table 9: In vitro chemosensitivity results expressed in the form of INT reduction inhibition % of control ..(107)

Table 10: Calculated cut-off values of the drug dosages. Its efficiency and its significance in correlation to the clinical outcome of therapy ...(111)

Table 11: Results of the correlation study in the pediatric age group of patients between the significant cut-off values and the risk factors ..(112)

Table 12: Correlation of the cut-off value of daunomycin dosage of 0.5 ug/ml with the different risk factors in the pediatric group(113)

Table 13: Correlation of the cut-off value of daunomycin dosage of 5ug/ml with the different risk factors in the pediatric group(114)

Table 14: Correlation of the cut-off value of vincristine dosage of 50 ug/ml with the different risk factors in the pediatric group(115)

Table 15: Results of the correlation study in the adult age group of patients between the significant cut-off values and the risk factors ..(116)

Table 16: Correlation of the cut-off value of daunomycin dosage of 0.5ug/ml with the different risk factors in adult group	(117)
Table 17: Correlation of the cut-off value of daunomycin dosage of 5ug/ml with the different risk factors in adult group	(118)
Table 18: Correlation of the cut-off value of vincristine dosage of of 50 ug/ml with the different risk factors in adult group	(119)
Table 19: Individual case correlation study of the pediatric age group of patients	(120)
Table 20: Individual case correlation study of the adult age groyp of patients	122)

LIST OF FIGURES

Figure 1: Primary sites of action of the antileukemic agents	(5)
Figure 2: Routes of elimination of commonly used antileukemic agents	(10)
Figure 3: Common acute and long-term toxicities of the antileukemic agents	(12)
Figure 4: Mechanisms of resistance of antileukemic agents ...	(14)
Figure 5: Pathways of selective lipophilic substance efflux in normal tissues and tumors	(19)
Figure 6: Reagents of the in vitro chemosensitivity testing	(74)
Figure 7: Equipments required for in vitro chemosensitivity testing	(79)
Figure 8: Instruments essential for in vitro chemosensitivity testing	(80)

Figure 9: In vitro chemsensitivity using microculture technique	(84)
Figure 10: In vitro chemosensitivity test just before reading	(85)
Figure 11: Leishman stained peripheral blood smear of the biphenotypic acute leukemia	(123')
Figure 12: Peroxidase stain of the same smear	(123')
Figure 13: Acid phosphatase stain of the same smear	(123'')
Figure 14: The calculated cut-off value of daunomycin 0.05ug/ml dosage	(124)
Figure 15: The calculated cut-off value of daunomycin 0.5ug/ml dosage	(125)
Figure 16: The calculated cut-off value of daunomycin 5ug/ml dosage	(126)

- Figure 17:** The calculated cut-off value of
vincristine 0.5 ug/ml dosage(127)
- Figure 18:** The calculated cut-off value of
vincristine 5ug/ml dosage(128)
- Figure 19:** The calculated cut-off value of
vincristine 50 ug/ml dosage(129)
- Figure 20:** The calculated cut-off value of
cyclophosphamide 0.5ug/ml dosage(130) .
- Figure 21:** The calculated cut-off value of
cyclophosphamide 5ug/ml dosage(131)
- Figure 22:** The calculated cut-off value of
cyclophosphamide 50ug/ml(132)
- Figure 23:** Correlation between INT% INH. RED. of DAUN.
0.5 ug/ml dosage and clinical outcome
in pediatric group(133)

- Figure 24:** Correlation between INT% INH. RED. of DAUN.
5 ug/ml dosage and clinical outcome
in pediatric group(134)
- Figure 25:** Correlation between INT% INH. RED. of VIN.
50ug/ml dosage and clinical outcome
in pediatric group(135)
- Figure 26:** Correlation between INT% INH. RED. of DAUN.
0.5 ug/ml dosage and clinical outcome
in adult group(136)
- Figure 27:** Correlation between INT% INH. RED. of DAUN.
5 ug/ml dosage and clinical outcome
in adult group(137)
- Figure 28:** Correlation between INT% INH. RED. of VIN.
50ug/ml dosage and clinical outcome
in adult group(138)

ABBREVIATIONS

Ab	= Antibody.
ABMT	= Autologous bone marrow transplantation.
Abs Bcs	= Absolute blast cell count.
AL	= Acute leukemia.
ALL	= Acute lymphoblastic leukemia.
ANLL	= Acute nonlymphoblastic leukemia.
APBSCT	= Autologous peripheral blood stem cell transplantation.
Ara-c	= Cytosine arabinoside.
AUL	= Acute undifferentiated leukemia.
BM	= Bone marrow.
BMT	= Bone marrow transplantation.
BsAb	= Bispecific antibody.
°C	= Degree centigrade.
CBC	= Complete blood picture.
CD	= Cluster of differentiation.
CFU-E	= Colony forming unit erythroid.
CFU-F	= Colony forming unit fibroblast .
CFU-GM	= Colony forming unit granulocyte macrophage.
CLL	= Chronic lymphoblastic leukemia.
CML	= Chronic myelogenous leukemia.
CMML	= Chronic myelomonocytic leukemia.
CNS	= Central nervous system.
⁵¹ Cr	= Radioactive chromium.
CR	= Complete remission.
CSF	= Colony stimulating factor.

DNA	= Deoxyribonucleic acid.
EDTA	= Ethylene diamine tetra-acetic acid.
Epo	= Erythropoietin.
Fab	= Antigen binding site of immunoglobulin.
FAB	= French American British.
FCS	= Fetal calf serum.
FI	= Failed induction.
G-CSF	= Granulocyte colony stimulating factor.
GM-CSF	= Granulocyte macrophage colony stimulating factor.
Hb	= Hemoglobin.
HGFs	= Hematopoietic growth factor.
HIV	= Human immunodeficiency virus.
³ H-Uridine	= Tritiated uridine.
IFN	= Interferone.
IgG	= Immunoglobulin G.
IL	= Interleukin.
IM	= Intramuscular.
INT	= P-iodonitrotetrazolium violet.
IV	= Intravenous.
Kd	= Kilo dalton.
LAK	= Lymphokine activated killer cells.
m ²	= Meter square.
MDR	= Multidrug resistance.
MDS	= Myelodysplastic syndrome.
mg	= Milligram.
ml	= Milliliter.
Mo Abs	= Monoclonal antibodies.

6-MP	= 6-mercaptopurine.
m-RNA	= Messenger ribonucleic acid.
MTT	= 4, 5 dimethylthiazole diphenyltetrazolium bromide.
NAP	= Neutrophil alkaline phosphatase.
ng	= Nanogram.
NK	= Nautral killer.
PB	= Peripheral blood.
PBMCs	= Peripheral blood mononuclear cells.
PBS	= Phosphate buffer saline.
RPM	= Revolution per minute.
RPMI	= Rose Park Medical Institute.
SC	= Subcutaneous.
TLC	= Total leucocyte count.
U	= Unit.
WBCs	= White blood cells.
Ug	= Microgram.
<	= Less than.
>	= More than.

CONTENTS

INTRODUCTION	(1)
AIM OF THE WORK	(3)
REVIEW OF LITERATURE	
-Treatment of Acute Leukemia	(4)
I- Chemotherapy	(4)
II- Immunotherapy	(33)
III- Bone marrow transplantation	(42)
-Hematopoietic Cell Culture	(45)
I - Current methodology	(45)
II- Uses in hematologic disorders	(49)
-Predictive Chemosensitivity Testing	(60)
SUBJECTS AND METHODS	(69)
RESULTS	(87)
DISCUSSION	(139)
SUMMARY AND CONCLUSION	(151)
RECOMMENDATIONS	(156)
REFERENCES	(157)
ARABIC SUMMARY	